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To the Editor
We thank Corrado Murtas et al. for their attention to our
paper that demonstrated the importance of anti-a enolase
(AENO) antibodies in primary and secondary membranous
nephropathy (MN). We emphasized the presence of anti-
AENO IgG1 and IgG4 subclasses of antibodies in primary
MN, and IgG1 and IgG3 subclasses in secondary MN,
including lupus nephritis (type V) and bucillamine-related
MN [1].
Murtas et al. reported the coexistence of different
circulating anti-podocyte antibodies in MN [2]. They
emphasized anti-AENO IgG4 antibodies. In the present
study, our data were consistent with theirs for primary
MN. However, for secondary MN, depending on
autoimmune type, IgG1 and IgG3 subclasses were pre-
dominant. They also commented a high prevalence of
anti-AENO IgG2 antibodies in lupus nephritis [3].
However, we did not detect anti-AENO IgG2 antibodies.
We compared the dot blot methods for anti-AENO
antibody between our study and Bruschi’s study
(Table 1). Major differences are blocking reagents for
nonspecific binding (skim milk versus BSA), and the
dilution titers of patients’ sera (1:200 versus 1:50) and
antibody for human IgG subclasses (1:500 versus
1:3000). Further study will be needed to confirm the best
method for detecting anti-AENO antibody.
Regard no detection of a-enolase in glomeruli from
primary MN in our study, we used human IgG-adsorbed
primary and secondary antibodies tested on frozen sections
gave no signal of a-enolase in glomeruli but still well
visible staining in proximal tubules. These discrepancies
between the two studies should be investigated further in a
future study.
We agree with Dr. Murtas’s comments that the combi-
nation of antigenic a-enolase epitopes and IgG subclasses
may differ by disease. We have to pay attention to anti-
AENO IgG subclasses, which may shed new light on the
mechanism of MN and other diseases.
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Table 1 A comparison on dot blot methods for anti-a enolase (AENO) antibody
Kimura et al. [1] Bruschi et al. [3]
Patients 25 patients with primary MN, and 13 patients with lupus
nephritis (V)
20 patients with lupus nephritis (II, III, IV, V)
Nitrocellulose
membranes
Nitrocellulose membranes (GE Healthcare, UK) Bio-Dot apparatus (Bio-Rad, Hercules, CA, USA)
Antigen: a-
enolase
Recombinant: home made Recombinant: Abnova Corporation (Taipei, Taiwan)
Antigen
amounts
10 lg/ml of enolase in Tween-PBS, for 60 min at room
temperature
100 ng of enolase in TBS, for 4 h at room temperature, and




5 % (w/v) skim milk (BD Difco, USA) 5 % (w/v) albumin in Tween-PBS
Patients’ sera Diluted 1:200 in Tween-PBS at room temperature overnight Diluted 1:50 in TBS-T (TBS-T 0.05 % v/v, 1 % w/v
albumin) for 6 h at room temperature, and then at 4 C
overnight
Antibody Peroxidase–conjugated mouse monoclonal antibodies to
human IgG1, IgG2, IgG3, IgG4 (Invitrogen, USA) at diluted
1:500 for 2 h at room temperature
HPR–anti human IgG1, IgG2, IgG3, IgG4 (Invitrogen,
USA) at diluted 1:3000 for 4 h at room temperature
Results 18 of 25 sera (IgG1 and IgG4, 11 patients; IgG4 alone, 6
patients; IgG1 alone, 1 patient) showed anti-AENO antibody
in primary MN, and positive IgG1 and IgG3 anti-AENO
antibody in 9 out of 13 patients with lupus nephritis (V)
Strong positive IgG2 anti-AENO antibody in lupus nephritis
(II, III, IV, V)
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